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Protein type III secretion systems (T3SSs) are organic nano-
syringes that achieve an energy-dependent translocation of
bacterial proteins through the two membranes of Gram-
negative organisms. Examples include the pathogenic systems
of animals, plants and symbiotic bacteria that inject factors
into eukaryotic cells, and the ﬂagellar export system that
secretes ﬂagellin. T3SSs possess a core of several membrane-
associated proteins that are conserved across all known
bacterial species that use this system. The Salmonella protein
InvA is one of the most highly conserved proteins of this core
of critical T3SS components. The crystal structure of a
C-terminal domain of InvA reveals an unexpected homology
to domains that have been repeatedly found as building blocks
of other elements of the T3SS apparatus. This suggests the
surprising hypothesis that evolution has produced a signiﬁcant
component of the apparatus structure through a series of
gene-duplication and gene-rearrangement events.
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1. Introduction
A number of Gram-negative bacterial pathogens, including
those causing disease in animals as well as in plants, utilize a
highly specialized nanomachine termed the type III secretion
system (T3SS) to achieve a remarkable translocation of
bacterial proteins across three membranes and directly into
the cytoplasm of the host organism (Galan & Wolf-Watz, 2006;
Cornelis, 2006). These virulence proteins, often called ‘effec-
tors’, hijack eukaryotic biochemical processes in sophisticated
ways for the beneﬁt of the pathogen (Cunnac et al., 2009;
Parsot, 2009; McGhie et al., 2009; Poueymiro & Genin, 2009;
Galan, 2009). The secretion machinery itself appears to be
highly conserved between different bacteria (Galan & Wolf-
Watz, 2006; Cornelis, 2006; Marlovits & Stebbins, 2010).
The engine of this complicated ‘molecular syringe’ consists
of a set of proteins in the inner membrane of these Gram-
negative organisms and extends into the cytoplasm, including
an ATPase and several key transmembrane proteins (Moraes
et al., 2008; Marlovits & Stebbins, 2010). InvA is a member of a
set of several inner membrane proteins that form this core of
the T3SS. Highly conserved across pathogenic bacteria, as well
as with a conserved homolog in the ﬂagellar system (FlhA),
InvA is critical to the functioning of the T3SS (Galan et al.,
1992; Ginocchio & Galan, 1995). However, the role of InvA,
why it is important and how it functions in the T3SS remainscompletely unknown. Apart from its sequence similarity to
analogous components of other T3SSs, InvA shows no
primary sequence similarity to any proteins of known func-
tion.
To begin to address some of these outstanding questions, we
determined the crystal structure of a C-terminal fragment of
InvA to 1.9 A ˚ resolution. This structure revealed the unex-
pected result that a set of structural domains that repeat in the
proteins forming the basal body are also present in InvA,
suggesting that large portions of the T3SS have been con-
structed from an evolutionarily conserved building block.
2. Materials and methods
2.1. Cloning, expression and purification of InvA(356–525)
An InvA fragment spanning residues 356–525 was ampliﬁed
by PCR from Salmonella genomic DNA. This domain was
ligated into a modiﬁed pCDFDuet-1 vector (EMD Chemicals
Inc., Gibbstown, New Jersey, USA) containing an afﬁnity tag
with 12 consecutive histidines and a 3C protease recognition
sequence to remove the tag. The protein was expressed in LB
medium containing 50 mgm l
 1 streptomycin and 1 mM iso-
propyl  -d-1-thiogalactopyranoside (IPTG) in Escherichia
coli BL21 (DE3) (Stratagene, La Jolla, California, USA) at
294 K overnight following induction at an OD600 of 0.8. Cells
were harvested by centrifugation and the pellet was dissolved
in a buffer (buffer A) consisting of 25 mM Tris–HCl pH 8.0,
200 mM NaCl, 5 mM imidazole pH 8.0, 1 mM phenylmethane-
sulfonyl ﬂuoride (PMSF) and lysed using an Emulsiﬂex C-5
cell homogenizer (Avestin Inc., Ottawa, Ontario, Canada).
The lysate was centrifuged at 16 000 rev min
 1 and 277 K for
30 min. InvA(356–525) protein was puriﬁed on Ni–NTA
Sepharose (Qiagen) equilibrated in buffer A and was eluted
from the column with buffer consisting of 25 mM Tris–HCl pH
8.0, 200 mM NaCl, 250 mM imidazole pH 8.0. Upon cleavage
with 3C protease, InvA(356–525) protein was concentrated
using a Amicon Ultracell 3K (Millipore) and loaded onto a
gel-ﬁltration column (Superdex 200 HighLoad 16/60, GE
Healthcare) equilibrated in buffer containing 25 mM Tris–
HCl, 200 mM NaCl, 2 mM dithiothreitol (DTT) using A ¨ KTA
FPLC. Selenomethionine-substituted protein was puriﬁed as
for the unlabeled protein.
2.2. Crystallization and structure determination of
InvA(356–525)
For crystallization, InvA(356–525) was concentrated to
25 mg ml
 1 in a buffer consisting of 25 mM Tris pH 8.0,
200 mM NaCl, 2 mM DTT. Crystals were grown by vapor
diffusion using hanging drops formed by mixing a 1:1 volume
ratio of InvA(356–525) protein solution and equilibration
buffer consisting of 1.6 M ammonium sulfate, 0.1 M MES pH
7.0, 8% dioxane at 296 K. For cryoprotection, crystals were
transferred directly into buffer consisting of 1.2 M ammonium
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Table 1
Data-collection and reﬁnement statistics for SeMet InvA(356–525).
Values in parentheses are for the high-resolution shell (1.92–1.85 A ˚ ).
Data collection
Space group I4
Unit-cell parameters (A ˚ ,  ) a = b = 83.7, c = 130.4,
  =   =   = 90.0
Resolution (A ˚ ) 19.29–1.85
No. of reﬂections 1313988
No. of unique reﬂections 75386
Rmerge† 6.5 (77.7)
I/ (I) 29.3 (2.1)
Completeness (%) 99.8 (100.0)
Redundancy 7.6 (7.6)
Reﬁnement
Resolution (A ˚ ) 19.29–1.85
No. of reﬂections 36968
Rwork/Rfree‡ (%) 21.0/23.8
No. of atoms
All atoms 2916
Protein 2745
Water 171
B factors (A ˚ 2)
All atoms 29.4
Protein 29.1
Water 33.7
R.m.s. deviations from ideal values
Bond lengths (A ˚ ) 0.016
Bond angles ( ) 1.519
† Rmerge =
P
hkl
P
i jIiðhklÞ h IðhklÞij=
P
hkl
P
i IiðhklÞ for the intensity (I)o fi
observations of reﬂection hkl.‡ R =
P
hkl
   jFobsj j Fcalcj
   =
P
hkl jFobsj, where Fcalc is
the model structure factor and 5% data were omitted for calculation of Rfree.
Figure 1
Overall structure of Salmonella InvA(359–523). (a) Overall fold of the InvA(359–523) monomer. Helices are shown in red and strands are shown in
yellow. The two domains are labeled, as are the spacer helix, the individual elements of secondary structure and the termini of the construct. (b)
Sequence and secondary-structural diagram of the InvA(359–523) monomer.sulfate, 0.1 M MES pH 7.0, 7% dioxane, 25% glycerol and
ﬂash-cooled to 113 K.
Reproducibility was a signiﬁcant challenge with the crystals
obtained. Many crystals produced data sets that could not be
effectively scaled and ‘good’ crystals were very rare amongst
the many that were screened. The model was phased and
reﬁned against a selenomethionine-substituted crystal which
diffracted and processed well. To date, obtaining a well
diffracting native data set has proved problematic.
Data were collected on Brookhaven National Synchrotron
light source beamline X29 as a single-wavelength anomalous
dispersion data set using selenomethionine-substituted
protein crystals and were processed using HKL-2000 (Otwi-
nowski & Minor, 1997). To increase the anomalous signal, two
additional selenomethionine sites were introduced into
InvA(356–525) by site-directed mutagenesis at residues
Leu383 and Leu470, and this mutant protein was puriﬁed
identically to the native. The crystals belonged to space group
I4, with unit-cell parameters a = b = 83.7, c = 130.4 A ˚ . There
were two InvA molecules in the asymmetric unit. Phases were
determined using SHELX (Sheldrick, 2008) and PHENIX
(Adams et al., 2010) and 90% of the ﬁnal model was built by
ARP/wARP (Langer et al., 2008). Cycles of manual building
and reﬁnement with REFMAC5 (Murshudov et al., 1997)
resulted in a model with an R and Rfree
of 21.0% and 23.8%, respectively, to
1.85 A ˚ resolution. The data-collection,
structure-determination and reﬁnement
statistics are summarized in Table 1.
3. Results and discussion
InvA of S. typhimurium is 685 amino
acids in length and the N-terminal 300
amino acids are comprised of seven
transmembrane helices. InvA also
possesses a large cytoplasmic domain
spanning residues  350–685. Both the
transmembrane and the cytoplasmic
domains have been shown to be critical
for T3SS activity (in InvA and in the
ﬂagellar homolog FlhA; Ginocchio &
Galan, 1995; McMurry et al., 2004). The
C-terminal domain is not membrane-
associated except by its attachment to
the N-terminal domain and can be
produced separately as a soluble entity.
Constructs of the cytoplasmic domain
of InvA that spanned the entire
C-terminal sequence following the pre-
dicted transmembrane regions proved
to be highly soluble and stable (data not
shown), but were recalcitrant to crys-
tallization. A series of limited proteo-
lytic digestions coupled with Edman
sequencing and mass-spectrometric
analysis identiﬁed several possible sub-
domains that were more amenable to crystallization. The
construct 356–525 produced crystals that diffracted well and
allowed the high-resolution structural determination of
roughly half of the InvA cytoplasmic domain (Table 1 and
Figs. 1, 2 and 3).
3.1. Overall structure of InvA(356–525)
The structure of InvA(356–525) reveals three subdomains:
two globular folds at the N-terminal end of the construct
followed by a long helix (spacer helix) that would presumably
lead to the far C-terminal subdomain(s) of the cytoplasmic
region (Figs. 1a and 1b). The far C-terminal helix may in fact
represent a portion (the beginning) of the subdomain fold that
is missing from the crystallized construct. Barring a confor-
mation change, this arrangement suggests that there are likely
to be two globular regions in the InvA cytoplasmic portion
that are spatially separated through the spacer helix. It is also
possible, however, that the far C-terminal region could travel
back and pack against the globular portion of the construct
that we have crystallized.
This domain of InvA is present as a dimer in the asymmetric
unit of the crystals, related by a twofold axis of symmetry. The
biological signiﬁcance of this dimer is uncertain, as the protein
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Figure 2
Conserved fold in multiple elements of the T3SS. Shown along with the two InvA domains are the
folds of GspD, EscJ, EscC and PrgH (PDB codes 3ezj, 1yj7, 3gr5 and 3gr0, respectively; Korotkov et
al., 2009; Yip et al., 2005; Spreter et al., 2009) divided into three classes based on protein fold. On the
left is a topology diagram for each class to illustrate the connectivity differences that are present in
these similar-appearing folds.research papers
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migrates as a monomeric species on size-exclusion chroma-
tography and the buried surface area of this interaction is less
than 500 A ˚ 2. The two copies of the protein are very similar,
with a root-mean-square deviation in C
  positions of 0.8 A ˚ .
Two regions of the protein contribute most to this variation:
the C-terminal helix of the truncated construct and an
extended region of 30 amino acids spanning residues 370–400.
In this latter extended region, covering two helices and a loop,
there are overall small translational shifts in the helices in the
alignment and in once place, involving residues 390–399, the
long loop between H2 and  2 adopts very different confor-
mations, both of which are well ordered in the electron-density
maps.
3.2. Presence of T3SS conserved folds
When the InvA structure is compared with structures
deposited in the Protein Data Bank (PDB), there is a
surprising ﬁnding. The subdomain spanning residues 428–478
possesses homology to the inner membrane ring-forming
protein EscJ (PrgK in Salmonella; Fig. 2). This domain also
appears in the outer membrane secretin ring, EscC, in the
E. coli T3SS and GspD of the type II secretion system (Spreter
et al., 2009). The recurrence of this fold in these ring-forming
proteins has led to the hypothesis that the domain itself is a
‘ring-forming’ motif (Spreter et al., 2009). However, InvA is
not known (or hypothesized) to form a ring and the packing of
these two domains in the InvA crystals differs markedly from
that of the EscJ tetramer that was used to model the ring (Yip
et al., 2005).
As has been noted (Marlovits & Stebbins, 2010), the
recurring three-dimensional folds in all of the ring-forming
Figure 3
Oligomeric assemblies of InvA and EscJ. (a) The crystallographic tetrameric assembly of the crystallized InvA construct is shown in two views side by
side, related by a 90  rotation about a vertical axis. Each of the chains is given a separate color and the COOH-terminus of the green polypeptide is
shown; the spacer helix is marked on the right image. (b) The EscJ tetramer present in the asymmetric unit of the crystals, alongside a surface
representation (colored by electrostatic potential) of the 24-mer ring model of EscJ proposed to form a portion of the inner membrane ring of the basal
body of the type III secretion system.proteins of the T3SS appear to be superﬁcially similar: there
is a three-stranded  -sheet core with two antiparallel and
interacting helices on one face of the sheet that run parallel to
the strands. Visually, the overall folds are superimposable. The
folds are distinct, however, in their topology (Fig. 2), with one
domain having a       fold (strand–helix–strand–strand–
helix) and the other having an       fold (helix–strand–
strand–helix–strand). The second InvA subdomain falls into
the former class.
Interestingly, the ﬁrst InvA subdomain (residues 358–417)
also has a core with two  -helices and a three-stranded
 -sheet, two strands of which are parallel. However, its
topology is distinct from the two classes mentioned above as
the strands possess different connectivity and the helices are
arranged very differently in three-dimensional space. Searches
of the PDB (Holm et al., 2008) return homology to a fold
found in diverse proteins of seemingly unrelated function,
such as the ‘small domain’ of bacterial RNase E and a portion
of MIF (macrophage migration inhibitory factor; PDB entries
2vmk and 2wkb; Koslover et al., 2008; Dobson et al., 2009).
3.3. Tetrameric InvA and comparisons to ring-forming
proteins
InvA(356–525) is present as a noncrystallographic dimer in
the crystals and forms a tetramer in crystal packing (Fig. 3),
despite the fact that this construct elutes from gel-ﬁltration
chromatography as a monomer (data not shown). The
tetramer is highly interdigitated, burying a total of nearly
10 000 A ˚ 2 of surface area (Fig. 3). Unlike the EscJ tetramer,
this tetramer is rotationally symmetric and there is no clear
manner in which it could be modeled as a ring along the lines
of the inner membrane ring of the basal body. Despite its
extensive contacts, the biological signiﬁcance of the crystallo-
graphic tetramer is uncertain. Whether the entire C-terminal
domain can adopt a similar tetrameric arrangement is unclear
and the packing could be a result of the truncation of the
domain and/or crystal packing. There is little support for the
tetramer outside of the crystals, as this construct, as well as the
entire C-terminal domain, run as monomers on gel-ﬁltration
chromatography.
4. Conclusions
T3SSs of Gram-negative bacteria are the critical virulence
devices of a large number of medically and agriculturally
relevant pathogens. Structural insight into this virulence
system will ﬁll an important gap in the knowledge of infectious
agents, as well as providing blueprints for the targeted
disruption of this system, potentially by therapeutic com-
pounds.
The structure of InvA reported here reveals an unexpected
homology to domains that have recently been shown to be
present in the channel-forming proteins of the pathogenic
T3SS. The presence of this fold in all of these elements of the
secretion machinery, from membrane-spanning channels to
soluble cytoplasmic components, indicates that the protein
T3SS has evolved in part from a set of common ‘bricks’:
proteins encoded by genes that are likely to be the result of
duplication and divergence. That the megadalton-sized
nanosyringe could be so constructed is a fascinating surprise,
illustrating the economy of biological evolution.
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